← Perspective Therapeutics, Inc. (CATX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Perspective Therapeutics, Inc. (CATX)
Pharmaceutical Preparations · market cap $292M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Perspective Therapeutics (CATX) is a small-cap radiopharmaceutical company with 138 employees and a ~$390M market cap focused on alpha-particle and lead-isotope targeted therapies. Its lead asset, [203Pb]VMT-α-NET, is in Phase 2 for unresectable neuroendocrine tumors, alongside Phase 2 programs in recurrent melanoma and pancreatic ductal adenocarcinoma. The company carries ~$54M cash against a runway of only ~5 months, making near-term financing a central concern.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| [203Pb]VMT-α-NET | Phase 2 | Neuroendocrine Tumors Unresectable |
| [203Pb]VMT01 | Phase 2 | Recurrent Melanoma (Skin) |
| [203Pb]Pb-PSV359 | Phase 2 | Pancreatic Ductal Adenocarcinoma |
Price & technical context
3-month
-25.1%
6-month
-38.5%
12-month
-20.7%
52-wk range
$2.05–$5.65
vs 50-day MA
-8.7%
vs 200-day MA
-24.6%
Realized vol
100.1%
Max drawdown
-89.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CATX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.